Eyevance Pharmaceuticals acquires global rights for Nexagon from OcuNexus Therapeutics
Eyevance Pharmaceuticals has made a significant move in the ophthalmic drug market by acquiring the global licensing rights for Nexagon, an advanced antisense oligomer drug, from OcuNexus Therapeutics. This strategic acquisition positions Eyevance at the forefront of developing new treatments for persistent corneal epithelial defect (PED), a challenging condition resistant to conventional therapies. Eyevance Pharmaceuticals […]